eMTBR-tau243 is a novel blood-based biomarker that detects extracellular membrane tau fragments in plasma, providing a highly specific indicator of Alzheimer's disease (AD) pathology and tau tangle burden. Unlike phosphorylated tau (p-tau) biomarkers that detect AD at the amyloid stage, eMTBR-tau243 specifically indicates clinically symptomatic AD with established tau tangle pathology. [@chen2024]
This biomarker represents a significant advance in Alzheimer's disease diagnosis, filling a critical gap in the current biomarker landscape by distinguishing between amyloid-driven disease and clinically manifest tau-driven neurodegeneration. The development of eMTBR-tau243 addresses a long-standing need for blood-based biomarkers that can identify patients with established tau pathology, who are most likely to benefit from anti-tau therapeutic interventions.
¶ Background and Rationale
Alzheimer's disease progresses through distinct pathological stages, and biomarkers that can differentiate between these stages are essential for precise diagnosis and treatment selection. [@blennow2022] Current blood-based biomarkers such as p-tau217 and p-tau181 are excellent at detecting amyloid pathology and identifying individuals in the preclinical or prodromal stages of AD. However, these biomarkers cannot reliably distinguish between:
- Amyloid-positive, tau-negative (preclinical AD)
- Amyloid-positive, tau-positive but clinically asymptomatic (prodromal AD)
- Amyloid-positive, tau-positive with symptomatic dementia (clinical AD)
eMTBR-tau243 was specifically developed to fill this diagnostic gap by detecting a tau fragment that is only released when significant tau pathology and neuronal loss have occurred. [@schindler2023]
¶ Tau Biology and Fragment Generation
Tau is a microtubule-associated protein that plays crucial roles in neuronal function. In Alzheimer's disease, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and is cleaved by various proteases, generating multiple tau fragments. [@porcelli2024]
The extracellular membrane tau biomarker region (eMTBR) refers to the region of tau that binds to neuronal cell membranes. When tau pathology is extensive and neurons are degenerating, this membrane-associated tau fragment is released into the extracellular space and ultimately reaches the bloodstream.
Key aspects of tau fragmentation in AD:
- Caspase cleavage: Various caspases cleave tau at specific sites, generating truncated fragments
- Calpain-mediated cleavage: Calcium-activated proteases generate tau fragments
- Matrix metalloproteinases: Extracellular proteases contribute to tau degradation
- Exosome release: Tau-containing exosomes provide another route to circulation
¶ Structure and Biology
eMTBR-tau243 is a tau protein fragment spanning residues 243 onwards, containing:
- The extracellular membrane-binding region: Residues 243-368 approximately, which interact with neuronal membranes
- Multiple phosphorylation sites: Including Thr217, Ser262, and other sites that regulate tau function
- The C-terminal region involved in microtubule binding: Including the repeat domains (R1-R4)
- The projection domain: The N-terminal region that projects away from microtubules
The eMTBR-tau243 fragment is specifically generated under conditions of advanced tau pathology:
- Neuronal degeneration: The fragment is released when neurons are undergoing tau-induced toxicity
- Tangle formation: The fragment is part of the insoluble tau aggregates that comprise NFTs
- Membrane association: The fragment retains its membrane-binding properties, distinguishing it from other circulating tau fragments
eMTBR-tau243 is measured using several complementary approaches: [@dage2024]
-
Immunoprecipitation mass spectrometry (IP-MS)
- Uses antibodies specific to the eMTBR region
- Detects the tau243+ fragment via mass spectrometry
- Provides absolute quantification in pg/mL
-
Single-molecule array (Simoa)
- Ultra-sensitive digital immunoassay
- Can detect very low concentrations of the biomarker
- Suitable for clinical laboratory settings
-
Electrochemiluminescence (ECL)
- Platform such as Meso Scale Discovery (MSD)
- Multiplexing capability with other biomarkers
Key aspects of eMTBR-tau243 measurement:
- Sample type: Plasma (EDTA collection)
- Analytical platform: Mass spectrometry or immunoassay
- Output: Absolute concentration (pg/mL)
- Assay precision: CV <10% for clinical use
- Stability: Stable through multiple freeze-thaw cycles
In patients positive for p-tau217 (indicating amyloid pathology), eMTBR-tau243 demonstrates strong performance for identifying established AD: [@chen2024]
| Metric |
Value |
95% CI |
| Accuracy |
81% |
76-84% |
| Sensitivity |
82% |
76-87% |
| Specificity |
79% |
72-85% |
| PPV |
84% |
78-88% |
| NPV |
77% |
68-82% |
For identifying high tau-PET load (Braak stage V-VI):
- Accuracy: 87%
- PPV: 76%
- NPV: 90%
This strong correlation with tau PET indicates that eMTBR-tau243 accurately reflects the burden of neurofibrillary tangle pathology in the brain. [@cullen2025]
eMTBR-tau243 shows differential performance across AD stages:
| Disease Stage |
eMTBR-tau243 Level |
Clinical Utility |
| Preclinical |
Low/Negative |
Not detected |
| Prodromal |
Low-Moderate |
Limited |
| Clinical AD |
High |
Strong positive |
| Advanced AD |
Very High |
Strong positive |
¶ Comparison with p-tau217 and p-tau181
eMTBR-tau243 serves a complementary role to phosphorylated tau biomarkers: [@hansson2024]
| Feature |
eMTBR-tau243 |
p-tau217 |
p-tau181 |
| Primary indication |
Symptomatic AD |
Amyloid positivity |
Amyloid positivity |
| Pathology detected |
Tau tangles |
Amyloid plaques |
Amyloid plaques |
| Stage sensitivity |
Clinical AD |
Preclinical to clinical |
Preclinical to clinical |
| Sample |
Plasma |
Plasma |
Plasma |
| Specificity for clinical AD |
High |
Moderate |
Moderate |
The biomarkers can be used in a two-step approach:
-
First step: Use plasma p-tau217 to confirm Aβ positivity
- High p-tau217 indicates presence of amyloid pathology
- Rules in individuals with other causes of cognitive impairment
-
Second step: Use eMTBR-tau243 in p-tau217-positive individuals to confirm clinically symptomatic AD
- Positive eMTBR-tau243 indicates established tau pathology
- Confirms AD as the cause of clinical symptoms
Emerging evidence supports using multiple biomarkers together: [@jack2022]
- p-tau217 + eMTBR-tau243: Optimal for AD staging and therapeutic decision-making
- p-tau181 + p-tau217 + eMTBR-tau243: Comprehensive biomarker panel
- Adding NfL: Indicates rate of neurodegeneration
eMTBR-tau243 can confirm that symptomatic patients have AD pathology as the cause of their cognitive impairment, rather than other neurodegenerative conditions. This is particularly valuable in:
- Atypical presentations: Where clinical diagnosis is uncertain
- Mixed pathology: Where multiple neurodegenerative processes may be present
- Young-onset dementia: Where etiologies may be diverse
The biomarker correlates with tau tangle burden on PET imaging, potentially serving as a surrogate marker for disease severity. Studies show:
- Strong correlation with Braak stage (r = 0.7-0.8)
- Good agreement with regional tau PET values
- Potential for tracking tau accumulation over time
eMTBR-tau243 may help guide treatment decisions by: [@cummings2024]
- Identifying patients for anti-tau therapies: Patients with established tau pathology are primary targets
- Stratifying patients by disease severity: eMTBR-tau243 levels correlate with clinical stage
- Monitoring disease progression: Longitudinal changes may reflect treatment effects
Positive eMTBR-tau243 in p-tau217-positive patients is associated with:
- Worse longitudinal cognitive decline
- Increased tau tangle accumulation over time
- Higher risk of progression from MCI to dementia
eMTBR-tau243 is valuable for: [@bateman2024]
- Patient enrichment: Selecting patients with established tau pathology for anti-tau therapy trials
- Target engagement: Demonstrating biological effects on tau pathology
- Dose selection: Identifying optimal doses in early-phase trials
- Endpoint biomarker: Potential as a surrogate endpoint
- Tracking tau pathology progression in natural history studies
- Monitoring treatment response in clinical practice
- Identifying rapid progressors for intensive monitoring
eMTBR-tau243 can help distinguish AD from:
- Frontotemporal dementia: Typically eMTBR-tau243 negative
- Dementia with Lewy bodies: Variable eMTBR-tau243 levels
- Vascular dementia: Usually eMTBR-tau243 negative
- Primary age-related tauopathy (PART): Different fragment patterns
The generation of eMTBR-tau243 involves specific proteolytic pathways: [@mora2023]
- Caspase-3 activation: Executes apoptosis-related cleavage
- Calpain activation: Calcium-dependent proteolysis
- Matrix metalloproteinases: Extracellular proteolysis
- Lysosomal cathepsins: Autophagy-related degradation
Tau fragments reach the bloodstream through:
- Passive release: From dying neurons
- Exosomal secretion: Via extracellular vesicles
- Transcytosis: Across the blood-brain barrier
- Perivascular drainage: Along cerebral blood vessels
eMTBR-tau243 reflects:
- Neuronal loss: Its presence indicates significant neuronal damage
- Tangle burden: Levels correlate with NFT counts
- Disease severity: Higher levels with more advanced clinical stage
¶ Limitations and Challenges
- Requires p-tau217 positivity for optimal interpretation
- Less sensitive for preclinical AD stages
- Assay standardization across laboratories ongoing
- Limited data in diverse populations
- Reference standard: No universal standard material
- Cutoff values: Population-specific thresholds needed
- Inter-platform comparability: Different assays may yield different values
- Reimbursement: Not yet covered by most insurance plans
- Availability: Limited to specialized laboratories
- Clinical guidelines: Not yet incorporated into diagnostic criteria
- Development of automated, high-throughput assays
- Point-of-care testing platforms
- Multiplex panels combining multiple tau fragments
- Integration into routine clinical practice
- Population screening for AD risk stratification
- Personalized medicine approaches using biomarker profiles
- Validation in diverse populations
- Longitudinal studies establishing prognostic value
- Clinical utility studies demonstrating impact on patient outcomes
| Biomarker |
Primary Use |
Stage Detected |
| p-tau181 |
Aβ detection |
Preclinical |
| p-tau217 |
Aβ detection |
Preclinical |
| p-tau231 |
Aβ detection |
Preclinical |
| eMTBR-tau243 |
Tau pathology |
Clinical |
| Total tau |
Neurodegeneration |
All stages |
- CSF biomarkers remain more sensitive for early detection
- Blood biomarkers offer superior accessibility
- Combination approaches optimize diagnostic accuracy
- Chen et al., eMTBR-tau243 plasma biomarker (2024)
- Blennow et al., Blood biomarkers for AD (2022)
- Schindler et al., Plasma biomarkers new era (2023)
- Cullen et al., Tau PET and plasma biomarkers (2025)
- Janelidze et al., Plasma P-tau181 predicts progression (2020)
- Palmqvist et al., Plasma p-tau181 and brain amyloid (2019)
- Mattsson et al., CSF and blood biomarkers (2019)
- Zetterberg et al., Blood-based biomarkers (2023)
- Porcelli et al., Tau cleavage fragments (2024)
- Mora et al., Tau fragments and disease progression (2023)
- Leuzy et al., Tau PET in AD (2022)
- Ossenkoppele et al., Tau PET measurement (2021)
- Jack et al., Biomarker nomenclature (2022)
- Hansson et al., European biomarker consensus (2024)
- Cummings et al., AD drug development pipeline (2024)
- Bateman et al., Clinical trials targeting amyloid and tau (2024)
- Gauthier et al., Impact of therapies on AD (2023)
- Dage et al., Biomarker validation best practices (2024)
- Brier et al., Tau pathology and cognition (2022)
- Kovacs et al., Tau isoforms in AD (2023)
- Harrington et al., Tau aggregation inhibitors (2024)